

Meiji to establish Singapore subsidiary to expand biz in ASEAN region

13 November 2025 | News

New subsidiary is expected to begin operations around spring 2026



Japan's Meiji Seika Pharma has decided to establish a local subsidiary in Singapore to strengthen its presence and expand its business in the ASEAN region through the commercialisation, marketing and distribution of pharmaceuticals, including vaccines. The new subsidiary is expected to begin operations around spring 2026.

The Singapore subsidiary will focus on commercialising, marketing and distributing pharmaceuticals, including vaccines, in the fields of infectious diseases, hematologic cancers, and lifestyle-related diseases.

Leveraging over 45 years of experience in manufacturing and marketing pharmaceuticals in Thailand and Indonesia, Meiji Seika Pharma will position Singapore as a hub for its business and commercial strategies across the ASEAN region, with the aim of further enhancing its influence and accelerating growth in the region.

Under the "Meiji Group 2026 Vision," Meiji Seika Pharma aims to become "a leading company in Asia in the field of infectious diseases". Through establishing its Singapore base, Meiji Seika Pharma intends to reliably supply essential products and contribute to the health and well-being of the people in the region.